Factor XII deficiency evaluated by thrombin generation assay.


Journal

Clinical biochemistry
ISSN: 1873-2933
Titre abrégé: Clin Biochem
Pays: United States
ID NLM: 0133660

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 29 07 2021
revised: 06 11 2021
accepted: 22 11 2021
pubmed: 30 11 2021
medline: 8 2 2022
entrez: 29 11 2021
Statut: ppublish

Résumé

Coagulation factor XII (FXII) plays a role in thrombin generation, fibrinolysis, inflammation, angiogenesis, chemotaxis and diapedesis. FXII deficiency is not associated with bleeding risk unlike other coagulation factors. We investigated thrombin generation assay (TGA) profile modification in FXII deficiency and the correlation with TGA and deficiency severity. TGA was performed in platelet poor plasma (PPP) with tissue factor (1 pmol/L) and phospholipid (4 µmol/L) standardized concentration. Thrombin generation profiles were compared in 54 patients with FXII deficiency, 25 healthy controls and 23 patients with hemophilia A (factor VIII (FVIII) deficiency. Patients with FXII deficiency were classified in three groups based on FXII activity (30-50%, 10-29%, <10%). FVIII deficiency was included as a bleeding control group. As expected, we found a correlation between FXII deficiency and activated partial thromboplastin time (aPTT). A decrease of thrombin generation was observed in healthy controls and all FXII deficiency groups. A decrease of endogenous thrombin potential (ETP), peak and velocity was observed in patients with FVIII deficiency compared to FXII deficiency. A decrease of thrombin generation was noted in patients with FXII deficiency and bleeding history compared to patients with FXII deficiency and thrombosis history. In this study, thrombin generation profiles were not sensitive to FXII deficiency. TGA could distinguish bleeding and thrombotic tendency in FXII deficiency. Our results should therefore be considered as exploratory and deserve confirmation.

Identifiants

pubmed: 34843733
pii: S0009-9120(21)00313-1
doi: 10.1016/j.clinbiochem.2021.11.014
pii:
doi:

Substances chimiques

Thrombin EC 3.4.21.5

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-47

Informations de copyright

Copyright © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Auteurs

Guillaume Feugray (G)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Fiston Kasonga (F)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Pierre Chamouni (P)

Rouen University Hospital, Hemophilia Care Center, F 76000 Rouen, France.

Virginie Barbay (V)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France; Rouen University Hospital, Hemophilia Care Center, F 76000 Rouen, France.

Marielle Fresel (M)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Marie Hélène Chretien (M)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Sabine Brunel (S)

Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Véronique Le Cam Duchez (V)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.

Paul Billoir (P)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France. Electronic address: paul.billoir@chu-rouen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH